Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine

Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine

Background: The nonavalent HPV (9vHPV) vaccine is indicated for active immunisation of individuals from the age of 9 years against cervical, vulvar, vaginal and anal premalignant lesions and cancers causally related to vaccine HPV high risk types 16, 18, 31, 33, 45, 52 and 58, and to the HPV low ris...

Full description

Saved in:
Bibliographic Details
Main Authors: Karl-Ulrich Petry (Author), Kaatje Bollaerts (Author), Paolo Bonanni (Author), Margaret Stanley (Author), Rosybel Drury (Author), Elmar Joura (Author), Susanne K. Kjaer (Author), Chris J. L. M. Meijer (Author), Didier Riethmuller (Author), Benoit Soubeyrand (Author), Pierre Van Damme (Author), Xavier Bosch (Author)
Format: Book
Published: Taylor & Francis Group, 2018-07-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items